KOD - Kodiak Sciences Inc.
IEX Last Trade
10.99
-0.070 -0.637%
Share volume: 6,124
Last Updated: Thu 26 Dec 2024 08:30:14 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$11.06
-0.07
-0.63%
Fundamental analysis
12%
Profitability
0%
Dept financing
7%
Liquidity
50%
Performance
15%
Performance
5 Days
6.70%
1 Month
50.46%
3 Months
264.21%
6 Months
331.00%
1 Year
224.67%
2 Year
49.55%
Key data
Stock price
$10.99
DAY RANGE
$9.88 - $11.40
52 WEEK RANGE
$2.26 - $11.60
52 WEEK CHANGE
$204.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Victor Perlroth
Region: US
Website: kodiak.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kodiak.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.
Recent news